Truvestments Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Truvestments Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-640	Closed	-$43K	–	199
2019 Q3	$43K	Hold	640	–	–	0.03%	285
2019 Q2	$55K	Hold	640	–	–	0.04%	263
2019 Q1	$57K	Buy	+640	New	+$59.3K	0.04%	243
2018 Q3	$62K	Buy	+640	New	+$63.9K	0.03%	344

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Truvestments Capital's BMRN Position: Q4 2019 in Review

Truvestments Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 640 shares — an estimated $43K sold.

Truvestments Capital first reported a position in BMRN in Q3 2018 and held it in 4 quarters. The position peaked at $62K in Q3 2018. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

Truvestments Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Truvestments Capital sold 640 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $43K.
Truvestments Capital first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 4 quarters.
Truvestments Capital's BioMarin Pharmaceuticals position peaked at $62K in Q3 2018.
467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Truvestments Capital's 13F filing for Q4 2019, filed 29 Jan 2020.